Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count

Abstract Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN‐RS‐T in the context of major platelet counts.

Dades bibliogràfiques
Autors principals: Marion Divoux, Alexia Plocque, Margaux Sevin, Laurent Voillat, Pierre Feugier, Agnès Guerci‐Bresler, Francois Girodon, Julien Broséus
Format: Article
Idioma:English
Publicat: Wiley 2020-09-01
Col·lecció:Clinical Case Reports
Matèries:
lenalidomide
myelodysplastic syndrome
myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombosis
myeloproliferative syndrome
thrombocytosis
Accés en línia:https://doi.org/10.1002/ccr3.3026

Internet

https://doi.org/10.1002/ccr3.3026

Ítems similars